Clinical Trials Logo

Marijuana Dependence clinical trials

View clinical trials related to Marijuana Dependence.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01827332 Active, not recruiting - Clinical trials for Marijuana Dependence

Effect of Oxytocin on Craving and Therapy Response

Start date: March 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the impact of a medication called oxytocin on craving, marijuana use, and therapy response in people who frequently use marijuana. .

NCT ID: NCT01574183 Active, not recruiting - Clinical trials for Marijuana Dependence

Vilazodone Treatment for Marijuana Dependence

Start date: August 2012
Phase: Phase 2
Study type: Interventional

Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.

NCT ID: NCT00875836 Active, not recruiting - Clinical trials for Marijuana Dependence

Buspirone Treatment for Marijuana Dependence

Start date: September 2009
Phase: Phase 4
Study type: Interventional

Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of buspirone for reducing marijuana use in marijuana-dependent adults. A contingency management (CM) intervention and motivational enhancement therapy (MET) will be incorporated to encourage study engagement and retention. It is hypothesized that buspirone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.